Literature DB >> 36004222

Strategy of delayed repair of total anomalous pulmonary venous connection in right atrial isomerism and functional single ventricle.

Eiri Kisamori1, Yasuhiro Kotani1, Fiza Komel Raja1, Junko Kobayashi1, Yosuke Kuroko1, Takuya Kawabata1, Shingo Kasahara1.   

Abstract

Objective: Repair of total anomalous pulmonary venous connection (TAPVC) in neonates with right atrial isomerism and functional single ventricle is challenging. In our novel strategy, primary draining vein stenting (DVS) was applied to patients with preoperative pulmonary vein obstruction to delay TAPVC repair. This study investigated our initial experience with a strategy of delayed TAPVC repair, incorporating DVS.
Methods: Twenty-nine patients with right atrial isomerism and functional single ventricle who had a severe obstruction in the course of draining veins, who required surgical or catheter intervention in their neonatal period were retrospectively reviewed (primary DVS: n = 11; primary TAPVC repair: n = 18).
Results: Patients in the primary DVS group had more mixed type TAPVC (primary DVS: n = 5, 45.5%; primary TAPVC repair: n = 2, 11.1%; P = .03) and required more systemic to pulmonary shunt surgeries during their lifetime (primary DVS: n = 9, 81.8%; primary TAPVC repair: n = 6, 33.3%; P = .047). Kaplan-Meier analysis showed that primary DVS repair was associated with improved survival compared with primary TAPVC repair (survival rates at 90 days, 1 year, 3 years and 5 years: primary DVS: 100%, 80%, 68.6%, and 54.9%; primary TAPVC repair: 55.6%, 38.9%, 38.9%, and 38.9%, respectively [P = .04]). Of the 4 patients who underwent stenting of the ductus venosus, 3 had elevated liver enzymes after surgical repair of TAPVC due to ductus venosus steal, which markedly improved after coil embolization of the stent. Conclusions: For neonates with obstructive TAPVC and functional single ventricle, our delayed TAPVC repair using primary DVS appeared to improve survival compared with the conventional strategy.
© 2022 The Author(s).

Entities:  

Keywords:  DVS, draining vein stenting; PVO, pulmonary vein obstruction; TAPVC, total anomalous pulmonary venous connection; congenital heart disease; neonate; right isomerism; stent implantation; surgical repair; total anomalous pulmonary venous connection

Year:  2022        PMID: 36004222      PMCID: PMC9390631          DOI: 10.1016/j.xjon.2021.11.012

Source DB:  PubMed          Journal:  JTCVS Open        ISSN: 2666-2736


Kaplan–Meier analysis showed improved survival of delayed strategy (P = .04). For neonates with obstructive total anomalous pulmonary venous connection, right atrial isomerism, and functional single ventricle, our strategy of delayed repair might improve survival. Repair of total anomalous pulmonary venous connection in neonates with right isomerism and functional single ventricle is challenging. Further verification of our delayed total anomalous pulmonary venous connection repair strategy would augment clinical management and guide decision-making in this unique entity. See Commentaries on pages 320 and 322. Although surgical outcomes in patients with total anomalous pulmonary venous connection (TAPVC) have improved over the past 2 decades, its management in patients with right atrial isomerism and functional single ventricle remains challenging.1, 2, 3 The Society of Thoracic Surgeons Congenital Heart Surgery Database revealed that the repair of TAPVC in such patients has a high mortality rate (43%). Younger age at TAPVC repair is also known to be associated with higher rates of mortality and postoperative pulmonary vein obstruction (PVO).,4, 5, 6 Some studies have suggested the possibility of stent implantation for obstructive drainage veins to delay the timing of surgical correction and improve survival., In our new strategy, primary draining vein stenting (DVS) was applied to patients with preoperative PVO to delay TAPVC repair. This study investigated the efficacy and problems of a strategy of delayed TAPVC repair in patients with right atrial isomerism and functional single ventricle.

Methods

We retrospectively reviewed all patients who underwent operative repair of TAPVC with right atrial isomerism and functional single ventricle at our institution between January 1990 and June 2020. Our hospital's institutional review board approved this study, and the requirement for written informed consent was waived because of the study's observational nature (IRB-2009-023; approval: October 23, 2020). Of the 50 patients, 29 consecutive patients had severe obstruction in the course of draining veins and needed surgical or catheter intervention in their neonatal periods. Preoperative obstruction was defined as a Doppler echocardiographic velocity of >1.2 m/s or a pressure gradient of 4 mm Hg or more or minimal diameter of draining vein of 1.5 mm or less or pulmonary congestion due to the narrowing of the draining veins requiring mechanical ventilation. These patients were divided into 2 groups: those who underwent primary DVS (n = 11) and those who underwent a primary TAPVC repair (n = 18; Figure 1). All imaging modalities were reviewed to confirm the anatomic diagnosis. Clinical information was extracted from the medical records, and operative notes were reviewed.
Figure 1

Of the 50 patients who underwent surgical repair of total anomalous pulmonary venous connection (TAPVC) with right atrial isomerism and functional single ventricle, 29 consecutive patients had a severe obstruction in the course of draining veins and needed surgical or catheter intervention in their neonatal periods. These cases were divided into those who underwent primary draining vein stenting (n = 11) or primary TAPVC repair (n = 18). Kaplan–Meier analysis showed a better survival in the primary draining vein stenting group compared with the primary TAPVC repair (P = .045).

Of the 50 patients who underwent surgical repair of total anomalous pulmonary venous connection (TAPVC) with right atrial isomerism and functional single ventricle, 29 consecutive patients had a severe obstruction in the course of draining veins and needed surgical or catheter intervention in their neonatal periods. These cases were divided into those who underwent primary draining vein stenting (n = 11) or primary TAPVC repair (n = 18). Kaplan–Meier analysis showed a better survival in the primary draining vein stenting group compared with the primary TAPVC repair (P = .045).

Delayed Strategy

In the 1990s, we performed primary TAPVC repair in all patients with right isomerism and functional single ventricle. Because younger age at TAPVC repair had begun to be known to be associated with higher mortality rates, since the 2000s, we have started to delay TAPVC repair if no PVO was present. In 2009, we performed the first case of primary DVS to delay TAPVC repair. Although we did not have a clear indication for DVS, we tended to apply DVS especially to patients who had complex anatomical features such as patients who needed systemic to pulmonary shunt or mixed-type TAPVC because this was the most difficult patient group that often struggled with postoperative management to balance systemic and pulmonary circulation. Because we achieved successful outcomes of the primary cases, we extended the criteria to use primary DVS. We did not routinely conduct a computed tomography scan or magnetic resonance imaging before the catheter intervention. Anatomical features were examined using echocardiography. TAPVC repair was delayed until patients had a progressive cyanosis or required other surgical interventions. Among 11 patients who underwent primary DVS at a median age of 8 (interquartile range, 4-16) days, 1 patient needed emergency stent removal with TAPVC repair because of stent migration. The patient had type Ib TAPVC and the landing zone was short. The stent migrated to the pulmonary artery after going through the atrium and the right ventricle during the stenting procedure. After this case, we consider a short landing zone as a contraindication for DVS. In 7 patients, primary draining vein stents were implanted in the vertical vein. Three patients had infracardiac type and 1 had mixed-type TAPVC who underwent primary DVS in the ductus venosus. Types of stents and their diameters are shown in Table E1.
Table E1

Type of stent used for primary draining vein stenting

PatientStent typeStent diameter (mm)
1Palmaz Genesis5 × 15
2Palmaz Genesis6 × 15
3BMX3.5 × 24
4Palmaz Genesis6 × 10
5Resolute Onyx4 × 22
6Resolute Integrity3.5 × 30
7Omnilink Elite7 × 19
8BMX3.5 × 18
9Nobori3.5 × 18
10Nobori3.5 × 24
11Genesis5 × 18

Palmaz Genesis are from Cardinal Health, BMX from Biosensors, Resolute Onyx and Resolute Integrity are from Medtronic, Omnilink Elite from Abbott, and Nobori is from Terumo. BMX, BioMatrix.

TAPVC Repair

TAPVC repair is usually performed with the patient under cardiac arrest and mild hypothermia without circulatory arrest. Conventional TAPVC anastomosis is performed in most patients. To minimize the thickness of the anastomosis, endocardial-to-endothelial bites were minimized.

Clinical Outcomes

The primary outcome was long-term survival, analyzed according to the Kaplan–Meier curve. We also investigated the clinical course of the patients after the procedures and patient characteristics including sex, birth weight, diagnosis after birth, and preoperative degree of atrioventricular valve regurgitation. Postoperative PVO was defined as a Doppler echocardiographic velocity of >1.2 m/s or a pressure gradient of 4 mm Hg or more. Catheter intervention was performed in patients with pulmonary congestion or high right ventricular pressure due to PVO. When the patients were refractory to catheter intervention, surgical PVO release was performed.

Statistical Analysis

All data were retrospectively analyzed. Data are presented as absolute numbers and percentages for categorical variables and as median values and interquartile ranges for continuous variables, unless stated otherwise. Dichotomous variables were compared using Fisher exact test, and χ2 test whereas the continuous variables were compared using the Mann–Whitney U test. P values are reported without correction for multiple tests. Kaplan–Meier calculations were performed for survival analyses. All statistical analyses were performed using Stata/SE version 16 (StataCorp).

Results

Patient Characteristics

Baseline characteristics of the study cohort are shown in Table 1. Patients in the primary DVS group had more mixed-type TAPVC (primary DVS: n = 5, 45.5%; primary TAPVC repair: n = 2, 11.1%; P = .036) and required more systemic to pulmonary shunt surgeries during their lifetime (primary DVS: n = 9, 81.8%; primary TAPVC repair: n = 6, 33.3%; P = .047).
Table 1

Patient characteristics

VariablePrimary draining vein stenting (n = 11)Primary TAPVC repair (n = 18)P value
Female sex5 (45.5)10 (55.6).60
Birth weight (IQR), kg2.6 (2.3-3.0)2.7 (2.6-3.1).31
TAPVC
 Supracardiac type3 (27.3)10 (55.6).14
 Infracardiac type3 (27.3)6 (33.3).73
 Mixed type5 (45.5)2 (11.1).03
Sutureless technique2 (18.2)0 (0).06
Functional single ventricle with common atrioventricular valve.08
 Unbalanced atrioventricular septal defect10 (90.9)11 (61.1)
 Common inlet right ventricle1 (9.1)7 (38.9)
 Common inlet left ventricle00
Pulmonary valve.10
 Stenosis9 (81.8)8 (44.5)
 Atresia2 (18.2)6 (33.3)
Major aortopulmonary collateral artery1 (9.1)0.19
Systemic venous drainage.06
 Bilateral superior vena cava6 (54.6)4 (22.2)
 Left-sided superior vena cava2 (18.2)1 (5.6)
Moderate or severe common atrioventricular valve regurgitation4 (36.4)2 (16.7).28
Systemic to pulmonary shunt9 (81.8)6 (33.3).04
Emergent intervention (within 24 h of birth)2 (18.1)8 (44.4).14

Data are presented as n (%) except where otherwise noted. TAPVC, Total anomalous pulmonary venous connection; IQR, interquartile range.

Patient characteristics Data are presented as n (%) except where otherwise noted. TAPVC, Total anomalous pulmonary venous connection; IQR, interquartile range. The clinical courses are presented in Tables 2 and 3. The median follow-up was 19.5 months in the overall cohort, with 33.4 (interquartile range, 9.3-62.7) months in the primary DVS group and 4.3 (interquartile range, 1.7-103) months in the primary TAPVC repair group (P = .28). In the primary TAPVC repair group, postoperative echocardiography data of 5 patients were not available because of early mortality. Postoperative PVO was noted in 5 patients in the primary DVS group (45.5%) and 6 in the primary TAPVC repair group (46.2%; P = .93). PVO reintervention, including catheter and surgery was performed in 5 patients (45.5%) in the primary DVS group and 3 in the primary TAPVC group (16.7%; P = .09; Figure 2; Table 2). Details of the postoperative PVO are described in Table E2. All patients who needed catheter intervention subsequently underwent PVO release surgery during follow-up.
Table 2

Clinical courses

Primary draining vein stenting (n = 11)Primary TAPVC repair (n = 18)P value
Follow-up period, months33.4 (9.3-62.7)4.3 (1.7-103).28
Primary draining stenting age, days8 (4-16)
Stenting site
 Vertical vein7
 Ductus venosus4
TAPVC repair age, days88 (58-106)8.5 (0-18)<.01
Postoperative PVO5 (45.5)6 (46.2).97
Reintervention for PVO5 (45.5)3 (16.7).09
Patients who reached or waiting for Glenn operation8 (72.7)9 (50).28
Fontan completion or awaiting Fontan operation5 (45.5)6 (33.3).38

Data are presented as median (interquartile range) or n (%) except where otherwise noted. TAPVC, Total anomalous pulmonary venous connection; PVO, pulmonary vein obstruction.

Table 3

Details of each patient

PatientTAPVC typeCardiac anatomySurgery before TAPVC repairConcomitant proceduresSubsequent proceduresAgeCause of death
Primary draining vein stenting
 1MixedSV, CAVV, PA, LSVCm-BTSLOS
 2SupracardiacDORV, Hypoplastic LV, CAVV, PS, MAPCA, Rt AoAm-BTSMAPCA ligationPVO release UnifocalizationCAVV repair8 MonthsRespiratory failure
 3InfracardiacSV, CAVV, PS, Bil. SVC, Rt AoA, PDAm-BTSCAVV repairCAVV repair7 MonthsHeart failure
 CAVV replacement1 Year
 PM implantation1 Year
 4SupracardiacSV, CAVV, PSm-BTSBDGCAVV repairBTS division10 MonthsTCPC graft embolism
 TCPCPulmonary valve closure1 Year
 5MixedSV, CAVV, PSCAVV repairMain pulmonary artery bandingm-BTSPulmonary artery valve closure28 Days
 6InfracardiacSV, PA, PDA, Rt AoA, Bil. SVCPDA bandingm-BTS
 7SupracardiacSV, CAVV, PS, Bil. SVC, Rt AoA, PDAPulmonary artery bandingPDA ligationBDGPulmonary artery bandingCAVV repairPVO release6 Months
 CAVV repairCRT implantation1 Year
 8MixedSV, CAVV, PS, Bil. SVC, Rt AoAMain pulmonary artery bandingBDG and PVO release (open stent)6 Months
 9MixedSV, CAVV, PSCAVV repairPulmonary artery plastyStent removalPVO release6 Months
 PVO releaseCAVV repair1 Year
 PVO release (open stent)CAVV repair1 Year
 BDGPulmonary artery semiclosure1 Year
 CAVV replacementCRT implantation3 Years
 Glenn take downm-BTS5 Years
 10InfracardiacSV, CAVV, PS, Bil. SVCm-BTSBDG and Pulmonary artery bandingPVO release7 Months
 PVO release10 Months
 PVO release1 Year
 PVO release (open stent)CAVV repair1 Year
 11MixedSV, CAVV, PA, LSVCm-BTS, Draining vein repairASD enlargementBDGPulmonary artery plastyCAVV repair1 Year
 TCPCCAVV repair3 Years
Primary TAPVC repair
 1InfracardiacSV, CAVV, PSLOS
 2SupracardiacSV, CAVV, PAm-BTSLOS
 3MixedSRV, PAm-BTSLOS
 4InfracardiacSRV, CAVV, PARV-pulmonary artery shuntCAVV repairHeart failure
 5InfracardiacSRV, CAVV, PSSepsis
 6SupracardiacSRV, CAVVRespiratory failure
 7SupracardiacSV, CAVV, PSpulmonary artery bandingRespiratory failure
 8SupracardiacSV, CAVV, PS, Bil. SVCRespiratory failure
 9InfracardiacDORV, CAVV, PARV-pulmonary artery shuntPVO release2 MonthsPVO
 10InfracardiacSV, CAVV, PA, Bil. SVCm-BTSBDGBTS division4 MonthsArrhythmia
 11SupracardiacSV, CAVV, PSBDGCAVV repair7 MonthsRespiratory failure
 Glenn take down8 Months
 12MixedSV, CAVV, PS, LSVCBDGpulmonary artery banding9 Months
 PM implantation9 Months
 Glenn take downCAVV repairPA debandingCRT upgrade1 Year
 13SupracardiacSRV, CAVV, PARV-pulmonary artery shuntPDA ligationBDG7 Months
 TCPCMaze2 Years
 PVO releaseFontan fenestration recreation6 Years
 14SupracardiacSV, CAVV, PS, Bil. SVCBDGCAVV repair4 Months
 TCPCCAVV repair2 Years
 PM implantation2 Years
 15SupracardiacSV, CAVV, Bil. SVC, Rt AoApulmonary artery bandingBilateral BDGpulmonary artery banding1 Year
 TCPC2 Years
 16SupracardiacSRV, CAVV, DORV, PS, Bil. SVCpulmonary artery bandingPVO release3 Months
 BDG6 Months
 TCPC3 Years
 17InfracardiacSV, CAVVpulmonary artery bandingBDGCAVV repair1 Year
 TCPC2 Years
 18SupracardiacDORV, CAVVPulmonary artery bandingBDGTCPC7 Months2 Years

TAPVC, Total anomalous pulmonary venous connection; SV, functional single ventricle; CAVV, common atrioventricular valve; PA, pulmonary atresia; LSVC, left superior vena cava; m-BTS, modified Blalock–Taussig shunt; LOS, low output syndrome; DORV, double outlet right ventricle; LV, left ventricle; PS, pulmonary stenosis; MAPCA, major aortopulmonary collateral artery; Rt AoA, right aortic arch; PVO, pulmonary venous obstruction; Bil. SVC, bilateral superior vena cava; PDA, patent ductus foramen; PM, pacemaker; BDG, bidirectional Glenn procedure; BTS, Blalock–Taussig shunt; TCPC, total cavopulmonary connection; CRT, cardiac resynchronization therapy; ASD, atrial septal defect; SRV, single right ventricle; RV, right ventricle.

Figure 2

Timing of surgeries and interventions focused on pulmonary venous obstruction. Primary total anomalous pulmonary venous connection repair was performed immediately after birth, whereas primary draining venous stenting delayed total anomalous pulmonary venous connection repair were done beyond the neonatal period. The overall mortality was 36.4% in the primary draining venous stenting group versus 61.1% in the primary total anomalous pulmonary venous connection repair group. Nine of 11 deaths in the primary total anomalous pulmonary venous connection group were observed before Glenn procedure.

Table E2

Pulmonary venous obstruction

PatientTAPVC typePostoperative PVO gradient (catheter), mm HgPostoperative peak velocity (echo) m/secInterventionStenotic siteNonconfluent PV
Primary draining vein stenting
 2Supracardiac1.4StentSurgical PVO releaseMultivessel+
 7Supracardiac31.5Surgical PVO releaseSingle vessel
 8Mixed1.2Surgical PVO releaseOpen stentBAPMultivessel+
 9Mixed102.1Surgical PVO releaseOpen stentBAPMultivessel
 10Infracardiac52Surgical PVO releaseOpen stentBAPMultivessel+
Primary TAPVC repair
 8Supracardiac1.3Anastomosis site
 9Infracardiac1.3Surgical PVO releaseMultivessel+
 12Mixed1.2Anastomosis site
 13Supracardiac1.4Surgical PVO releaseMultivessel
 16Supracardiac2.5Surgical PVO releaseMultivessel
 18Supracardiac1.4Anastomosis site

TAPVC, Total anomalous pulmonary venous connection; PVO, pulmonary venous connection; PV, pulmonary vein; BAP, balloon angioplasty; +, nonconfluent pulmonary vein; −, confluent pulmonary vein.

Clinical courses Data are presented as median (interquartile range) or n (%) except where otherwise noted. TAPVC, Total anomalous pulmonary venous connection; PVO, pulmonary vein obstruction. Details of each patient TAPVC, Total anomalous pulmonary venous connection; SV, functional single ventricle; CAVV, common atrioventricular valve; PA, pulmonary atresia; LSVC, left superior vena cava; m-BTS, modified Blalock–Taussig shunt; LOS, low output syndrome; DORV, double outlet right ventricle; LV, left ventricle; PS, pulmonary stenosis; MAPCA, major aortopulmonary collateral artery; Rt AoA, right aortic arch; PVO, pulmonary venous obstruction; Bil. SVC, bilateral superior vena cava; PDA, patent ductus foramen; PM, pacemaker; BDG, bidirectional Glenn procedure; BTS, Blalock–Taussig shunt; TCPC, total cavopulmonary connection; CRT, cardiac resynchronization therapy; ASD, atrial septal defect; SRV, single right ventricle; RV, right ventricle. Timing of surgeries and interventions focused on pulmonary venous obstruction. Primary total anomalous pulmonary venous connection repair was performed immediately after birth, whereas primary draining venous stenting delayed total anomalous pulmonary venous connection repair were done beyond the neonatal period. The overall mortality was 36.4% in the primary draining venous stenting group versus 61.1% in the primary total anomalous pulmonary venous connection repair group. Nine of 11 deaths in the primary total anomalous pulmonary venous connection group were observed before Glenn procedure.

Survival and Fontan Achievement

Kaplan–Meier analysis showed a better survival in the primary DVS group than in the primary TAPVC repair (survival rates at 90 days, 1 year, 3 years and 5 years: primary DVS: 100%, 80%, 68.6%, and 54.9% vs primary TAPVC repair: 55.6%, 38.9%, 38.9%, and 38.9%, respectively [P = .045]; Figure 3; Video 1). Four patients died in the primary DVS group because of respiratory failure due to hypoplastic trachea, low output syndrome, heart failure after surgery, and thromboembolism of the conduit after Fontan operation (Table 3). Of the 11 patients who died in the primary TAPVC repair group, 9 patients died within 100 days before Glenn procedure mainly because of heart failure and low output syndrome. All 11 patients with primary DVS underwent TAPVC repair later at a median age of 88 days, whereas primary TAPVC repair was performed at a median age of 8.5 days (P < .01). Five patients (45.5%) achieved Fontan completion or awaiting Fontan procedure in the primary DVS group, whereas 6 patients (33.3%) completed Fontan procedure in the primary TAPVC group (Figure 4).
Figure 3

Kaplan–Meier analysis of overall survival for each group. Kaplan–Meier analysis showed that primary draining venous stenting repair was associated with improved survival compared with primary total anomalous pulmonary venous connection repair (survival rates at 90 days, 1 year, 3 years, and 5 years): primary draining venous stenting: 100%, 80%, 68.6%, and 54.9%, respectively; and primary total anomalous pulmonary venous connection repair: 55.6%, 38.9%, 38.9%, and 38.9%, respectively (95% CI, 0.26-0.63; P = .045). CI, Confidence interval.

Figure 4

Diagram of postsurgical outcome. All 11 patients with primary draining venous stenting underwent total anomalous pulmonary venous connection (TAPVC) repair later at a median age of 88 days. Five patients (45.5%) achieved Fontan completion or awaiting Fontan operation in the primary draining venous stenting group, whereas 6 patients (33.3%) achieved Fontan operation in the primary TAPVC group. BDG, Bidirectional Glenn procedure.

Kaplan–Meier analysis of overall survival for each group. Kaplan–Meier analysis showed that primary draining venous stenting repair was associated with improved survival compared with primary total anomalous pulmonary venous connection repair (survival rates at 90 days, 1 year, 3 years, and 5 years): primary draining venous stenting: 100%, 80%, 68.6%, and 54.9%, respectively; and primary total anomalous pulmonary venous connection repair: 55.6%, 38.9%, 38.9%, and 38.9%, respectively (95% CI, 0.26-0.63; P = .045). CI, Confidence interval. Diagram of postsurgical outcome. All 11 patients with primary draining venous stenting underwent total anomalous pulmonary venous connection (TAPVC) repair later at a median age of 88 days. Five patients (45.5%) achieved Fontan completion or awaiting Fontan operation in the primary draining venous stenting group, whereas 6 patients (33.3%) achieved Fontan operation in the primary TAPVC group. BDG, Bidirectional Glenn procedure.

Liver Damage

Of the 4 patients who underwent stenting of the ductus venosus, 3 had liver damage 2 to 3 days after TAPVC repair. Before TAPVC repair, none of the 3 patients had liver damage and they tolerated to the stents. Their aspartate transaminase and alanine transaminase levels were elevated to 1684 to 5945 U/L and 566 to 3059 U/L, respectively. Ultrasound showed blood flow from the liver through the portal vein to the ductus venosus where the stent was applied. The patients were immediately transferred to the catheterization lab to embolize the stent, which improved the aspartate transaminase and alanine transaminase levels. Figure 5 shows the contrast-enhanced computed tomography images of the 3 patients who underwent stenting of the ductus venosus.
Figure 5

Contrast enhanced computed tomography images of patients with ductus venous stenting. Three of the 4 patients who underwent stenting of the ductus venosus had elevated aspartate transaminase and alanine transaminase levels after total anomalous pulmonary venous connection repair. The cause of liver damage after total anomalous pulmonary venous connection repair is a result of increased blood flow from the portal vein to the ductus venosus due to decreased blood flow from the pulmonary vein to the ductus venosus. Increased shunt across the ductus venosus decreased blood flow to liver, resulting in liver damage. The elevated aspartate transaminase and alanine transaminase levels became normal soon after stent embolization.

Contrast enhanced computed tomography images of patients with ductus venous stenting. Three of the 4 patients who underwent stenting of the ductus venosus had elevated aspartate transaminase and alanine transaminase levels after total anomalous pulmonary venous connection repair. The cause of liver damage after total anomalous pulmonary venous connection repair is a result of increased blood flow from the portal vein to the ductus venosus due to decreased blood flow from the pulmonary vein to the ductus venosus. Increased shunt across the ductus venosus decreased blood flow to liver, resulting in liver damage. The elevated aspartate transaminase and alanine transaminase levels became normal soon after stent embolization.

Discussion

TAPVC repair in patients with right atrial isomerism and functional single ventricle is known to have high mortality rates.1, 2, 3 The risk for TAPVC repair is higher when performed in neonates because this subset of patients usually represents the most severe end of the TAPVC spectrum with features including hypoxia, hypercapnia, or acidosis.,4, 5, 6 Because there was no alternative to delay emergency TAPVC repair in patients with pulmonary obstruction, the outcome was disappointing because of high mortality rates soon after the first operation.,, In our institute, a delayed strategy was applied to patients with right atrial isomerism and obstructed TAPVC using primary DVS. Since 2009, when we performed the first case of primary DVS to delay TAPVC repair, it was performed in 11 neonates. This study showed the initial experience with improved survival in primary DVS compared with the conventional primary TAPVC repair. It is important to note that in the primary TAPVC repair group, most patients died soon after surgery because of low output syndrome and heart failure as the result of unbalanced systemic-to-pulmonary blood flow. Patients who undergo TAPVC repair in the neonatal period often have poor lung conditions with high pulmonary resistance. In such patients, controlling pulmonary circulation is difficult, especially in patients with systemic to pulmonary shunts. This causes low cardiac output, ventricular dysfunction, and atrioventricular valve regurgitation, which subsequently results in a lethal condition.,4, 5, 6 TAPVC repair during cardiopulmonary bypass, in addition to systemic to pulmonary shunt, is far more invasive compared with drainage vein stenting. As such, a delayed TAPVC repair strategy has the advantage that TAPVC repair can be postponed beyond the neonatal period by avoiding TAPVC repair and systemic to pulmonary shunt. Postoperative PVO is a well known complication associated with pulmonary venous hypertension, pulmonary vascular disease, and increased morbidity and mortality., Younger age at TAPVC repair might be associated with postoperative PVO because of the small anastomotic site. Therefore, a strategy of delayed TAPVC repair was expected to reduce postoperative PVO. However, postoperative PVO was noted in 5 patients in the primary DVS group (45.5%) and 6 in the primary TAPVC repair group (46.2%; P = .93); the primary DVS group still had a high postoperative PVO rate. There are several possible reasons for this finding. First, the primary TAPVC repair group had a high early mortality rate, and some patients were not assessed for PVO before they died. Second, more mixed-type TAPVC was observed in the primary DVS group, which could be a high risk for postoperative PVO. Finally, only 2 patients had a sutureless technique and the result might have been different if the technique was used more frequently for those with infracardiac and mixed-type TAPVC. Although this study was not able to prove the benefit of delayed TAPVC repair in the occurrence of postoperative PVO because of the small number of patients studied, further investigation is necessary to determine the effect of this strategy. Stenting of the ductus venosus in patients with TAPVC and right isomerism has been previously reported. However, problems of liver damage after TAPVC repair have not been studied. In this study, 3 of the 4 patients who underwent stenting of the ductus venosus had elevated aspartate transaminase and alanine transaminase levels after TAPVC repair. The cause of liver damage after TAPVC repair is a result of increased blood flow from the portal vein to the ductus venosus because of decreased blood flow from the pulmonary vein to the ductus venosus. Increased shunt across the ductus venosus decreased blood flow to the liver, resulting in liver damage. The elevated aspartate transaminase and alanine transaminase levels became normal soon after coil embolization of the stent. Therefore, careful monitoring of liver enzymes is recommended for 1 to 2 days after TAPVC repair or stenting of the ductus venosus, and early intervention, including catheter coil embolization of the stent should be considered. In our recent case, we planned percutaneous occlusion of the ductus venosus in anticipation of rapid liver function abnormalities after TAPVC repair (Y. Imai, unpublished data). Our study has some limitations. This study was conducted retrospectively in a single center and consequently included a small number of patients. There were baseline differences among the 2 groups, which might have affected outcomes. A difference in survival rates might also have affected the secondary outcomes.

Conclusions

For neonates with obstructive TAPVC, right atrial isomerism, and functional single ventricle, our strategy of delayed TAPVC repair using primary DVS might delay the timing and improve survival compared with the conventional strategy. When TAPVC repair is performed after ductus venosus stenting, we should be aware of potential liver damage and consider early catheter intervention.

Webcast

You can watch a Webcast of this AATS meeting presentation by going to: https://aats.blob.core.windows.net/media/21%20AM/AM21_CPlen/AM21_CPLEN_04.mp4.

Conflict of Interest Statement

The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
  10 in total

1.  Repair of Total Anomalous Pulmonary Venous Connection: Risk Factors for Postoperative Obstruction.

Authors:  Brian R White; Deborah Y Ho; Jennifer A Faerber; Hannah Katcoff; Andrew C Glatz; Christopher E Mascio; Paul Stephens; Meryl S Cohen
Journal:  Ann Thorac Surg       Date:  2019-03-16       Impact factor: 4.330

2.  Long-term results of treatments for functional single ventricle associated with extracardiac type total anomalous pulmonary venous connection.

Authors:  Takaya Hoashi; Koji Kagisaki; Tatsuya Oda; Masataka Kitano; Kenichi Kurosaki; Isao Shiraishi; Toshikatsu Yagihara; Hajime Ichikawa
Journal:  Eur J Cardiothorac Surg       Date:  2012-11-22       Impact factor: 4.191

3.  Heterotaxy patients with total anomalous pulmonary venous return: improving surgical results.

Authors:  David L S Morales; Brandi E Braud; Justin H Booth; Daniel E Graves; Jeffrey S Heinle; E Dean McKenzie; Charles D Fraser
Journal:  Ann Thorac Surg       Date:  2006-11       Impact factor: 4.330

4.  Surgical results for functional univentricular heart with total anomalous pulmonary venous connection over a 25-year experience.

Authors:  Yuki Nakayama; Takeshi Hiramatsu; Yusuke Iwata; Toru Okamura; Takeshi Konuma; Goki Matsumura; Kenji Suzuki; Kyoko Hobo; Toshio Nakanishi; Hiromi Kurosawa; Kenji Yamazaki
Journal:  Ann Thorac Surg       Date:  2011-12-28       Impact factor: 4.330

5.  Total Anomalous Pulmonary Venous Connection: The Current Management Strategies in a Pediatric Cohort of 768 Patients.

Authors:  Guocheng Shi; Zhongqun Zhu; Jimei Chen; Yanqiu Ou; Haifa Hong; Zhiqiang Nie; Haibo Zhang; Xiaoqing Liu; Jinghao Zheng; Qi Sun; Jinfen Liu; Huiwen Chen; Jian Zhuang
Journal:  Circulation       Date:  2016-11-15       Impact factor: 29.690

6.  Successful stenting of the ductus venosus in 2 neonates with asplenia syndrome complicated by infracardiac type total anomalous pulmonary venous connection.

Authors:  Takashi Higaki; Eiichi Yamamoto; Takeshi Nakano; Masaaki Ohta; Hidemi Takata; Kikuko Murao; Toshiyuki Chisaka; Tomozo Moritani; Mitsugi Nagashima; Fumiaki Shikata; Eiichi Ishii
Journal:  J Cardiol Cases       Date:  2009-12-03

7.  Factors associated with mortality and reoperation in 377 children with total anomalous pulmonary venous connection.

Authors:  Tara Karamlou; Rebecca Gurofsky; Eisar Al Sukhni; John G Coles; William G Williams; Christopher A Caldarone; Glen S Van Arsdell; Brian W McCrindle
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

8.  Improved current era outcomes in patients with heterotaxy syndromes.

Authors:  Petros V Anagnostopoulos; Jeffrey M Pearl; Courtney Octave; Mitchell Cohen; Angelika Gruessner; Erika Wintering; Michael F Teodori
Journal:  Eur J Cardiothorac Surg       Date:  2009-02-23       Impact factor: 4.191

9.  Contemporary Outcomes of Surgical Repair of Total Anomalous Pulmonary Venous Connection in Patients With Heterotaxy Syndrome.

Authors:  Muhammad S Khan; Roosevelt Bryant; Sung H Kim; Kevin D Hill; Jeffrey P Jacobs; Marshall L Jacobs; Sara K Pasquali; David L S Morales
Journal:  Ann Thorac Surg       Date:  2015-04-23       Impact factor: 4.330

10.  Stenting as a possible new therapeutic strategy to the obstructed TAPVC.

Authors:  Toshiyuki Itoi
Journal:  J Cardiol Cases       Date:  2013-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.